Stepan (NYSE:SCL – Get Free Report)’s share price hit a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $59.55 and last ...
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback